

OPEN

Allylpyrocatechol, isolated from betel leaf ameliorates thyrotoxicosis in rats by altering thyroid peroxidase and thyrotropin receptors

Sunanda Panda¹, Malabika Sikdar², Sagarika Biswas³, Rajesh Sharma¹ & Anand Kar⁴

Allylpyrocatechol (APC) was isolated from betel leaf and its possible role in L-thyroxin (L-T₄)-induced thyrotoxic rats was evaluated. The disease condition, thyrotoxicosis was confirmed by higher levels of thyroid hormones and low thyrotropin (TSH) in serum. Increased hepatic activities of 5'-mono-deiodinase(5'D1), glucose-6-phosphatase (G-6-Pase); serum concentrations of alanine transaminase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase(LDH) and tumour necrosis factor-alpha(TNF- α) were observed in thyrotoxic rats. Hepatic lipid peroxidation(LPO) was also increased and the endogenous antioxidants were depleted in these rats. In western blot analysis thyroid peroxidase expression was found to be reduced, whereas thyrotropin receptor(TSHR) expression was enhanced in thyroid gland of these animals. On the other hand, APC treatment in thyrotoxic rats decreased the levels of serum thyroid hormones, ALT, AST, TNF- α and LDH, as well as hepatic 5' D1 and G-6-Pase activities. However, it increased the serum TSH levels. APC also reduced the hepatic LPO and increased the cellular antioxidants in thyrotoxic rats. However, expression of TSHR was inhibited and TPO was increased by APC. The test compound also improved histological features in both liver and thyroid. Present report appears to be the first one that indicates the positive role of APC in ameliorating T₄-induced thyrotoxicosis.

Thyroid hormones, triiodothyronine (T₃) and thyroxin (T₄) are known to regulate all most all body functions including development, differentiation and metabolism^{1,2}. Compared to T₄, T₃ is considered to be more biologically active. While T₄ is synthesized only in the thyroid gland, about 90% of the total circulating T₃ is produced by the conversion of T₄ to T₃ in the extra-thyroidal tissues, that is catalysed by the enzyme type 1 iodothyronine 5'-deiodinase (5'D-1) in the liver, kidney, and skeletal muscle and to some extent in thyroid gland^{3,4}. To assess the thyroid function normally the serum levels of T₃, T₄ and TSH are estimated. Low or high levels thyroid hormones in circulation are associated with thyroid dysfunction as well as liver disorder.

Thyrotoxicosis, a condition of thyroid dysfunction is a clinical syndrome of hyper metabolism resulting from increased levels of serum T₄ and/or T₃ that affect all most all the physiological systems^{5,6}. Thyrotoxicosis can result from a destructive process in the thyroid leading to an unregulated release of stored thyroid hormones without increased production⁷. This problem, if not treated properly may end up in serious abnormalities.

Earlier some investigations were made in thyrotoxic rat model showing marked increase in serum T₃ and T₄ levels with a loss of body weight⁷⁻⁹. In a recent investigation we have also shown that the experimental thyrotoxic rat model can be developed by the intraperitoneal injection of L-T₄ (500 μ g/kg) once daily for 12 consecutive days and this model was found to be quite suitable to study the effects of bioactive compound¹⁰.

¹School of Pharmacy, Devi Ahilya University, Indore, India. ²Department of Zoology, Dr. Hari Singh Gour Vishwavidyalaya, Saugar, India. ³Department of Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India. ⁴Thyroid Research laboratory, School of Life Sciences, Devi Ahilya University, Indore, India. Correspondence and requests for materials should be addressed to S.P. (email: spanda4@rediffmail.com)




Figure 1. (a) Chemical structure of allypyrocatechol (APC), isolated from *Piper betel* leaf extract. (b) HPLC chromatogram of standard APC with retention time of 5.074 minutes. (c) HPLC chromatogram of sample APC showing retention time at 5.073 min. It nearly matches with that of the standard.

In recent years, a tremendous increase in the interest has been generated on the identification of novel compounds that may have potential in clinical medicine. However, nothing much had been investigated with respect to the regulation of thyrotoxicosis by plant derived active compounds.

Piper betel (family, Piperaceae) is a widely cultivated plant in the tropical and subtropical regions of the world, particularly in India, Srilanka, Malaysia, Thailand, Taiwan and other South-east Asian countries. Although its leaves are used as betel quid, it also possesses hepatoprotective, antiulcer, antioxidative and anti-inflammatory activities^{11,12}. However, till date nothing has been reported on the thyroid regulating potential of any of its bio-active compounds. Allypyrocatechol (APC), a major phenolic constituent of betel leaf was reported to possess hepatoprotective, anti-inflammatory, antioxidative, and antiulcer activities^{13–17}. As in our earlier study, betel leaf crude extract was found to be thyroid-inhibitory in nature¹⁸; it was presumed that there could be an active compound in betel leaf that can regulate thyroid dysfunction. In this investigation we have isolated allypyrocatechol the main phenolic compound of betel leaf and evaluated its thyroid inhibitory effects, if any, in T_4 -induced thyrotoxic rats. We also compared its activity with that of a conventional thyroid inhibitory drug, propylthiouracil (PTU) that primarily inhibits synthesis of thyroid hormones by reducing organification of iodide and coupling of iodothyronines¹⁹. PTU also decreases the conversion of T_4 to T_3 in peripheral tissues by inhibiting the outer ring deiodination of T_4 ²⁰. Towards better understanding on the mode of action of the test compound, expressions of thyroid peroxidase and thyrotropin receptor were also examined.

Results

Isolated compound and its characterization. On the basis of spectroscopic analyses, the compound (Fig. 1a) was identified as allypyrocatechol. This compound was obtained as light yellow oil with a yield of 0.92% (w/w) and its molecular weight was deduced from gas chromatography mass spectroscopy (GC-MS) at m/z as 150.17. 1H NMR and ^{13}C NMR data are in full agreement with the proposed structure of APC²¹. Purity of APC was checked by high-performance liquid chromatography (HPLC) and was found to be 98.2%. Figure 1b,c show the HPLC chromatogram.

Prediction of the chemical structure and formula of APC was made from the GC-MS spectrum (Fig. 2). Based on the fragmentation route, the molecular formula was deduced as $C_9H_{10}O_2$. According to the database (library search report NIST05), the high similarity (99%) was achieved for the compound with chemical name 3,4-Dihydroxyallylbenzene. Some more characteristics of APC are: IR = 3309, 1606.5, 1408.85, 1272.41, 1184.26, 909.63, 863.34, 784.47 cm^{-1} ; 1H NMR: δ 3.29 (d, $J = 6.5$ Hz), 2 H, ArCH₂), 4.99–5.04 (m, 2 H, olefin), 5.36 (broad, 2 H, 2xAr-OH) and 5.08–6.01 (m, 1 H, olefin, 6.56–6.76) and ^{13}C NMR ($CDCl_3$, 50 MHz): δ 39.33, 115.28, 115.77, 122.65, 131.98, 132.84, 140.77, 143.1. The IR and NMR (^{13}C and 1H) spectra are given in Supplementary Section (Fig. S1a–c).

Changes in body weight. While in T_4 - treated thyrotoxic animals, a significant decrease in final body weight (b.wt.) was observed (by 23.24%), no significant differences were seen between initial and final b.wt. of animals in control, T_4 + APC and in T_4 + PTU groups. However, it was significantly increased (by 8.36%) in animals treated with APC only (Table 1).

Changes in thyroid hormones and 5′deiodinase-1 activity. While in L- T_4 -induced rats there was a significant increase in serum levels of T_3 , T_4 and in hepatic 5′D1 activity; a decrease in the thyrotropin (TSH) level was noticed, indicating the thyrotoxic condition. However, treatment with APC nearly normalized the serum thyroid hormone concentrations in T_4 -induced rats (Fig. 3a). In PTU + T_4 treated animals also, thyroid hormones




Figure 2. The GC-MS spectrum showing the structure of the APC, molecular formula (C₉H₁₀O₂) and molecular mass, 150.174.

Parameters	Cont	APC	T ₄	T ₄ + APC	T ₄ + PTU
Body weight (g)					
Initial	171.2 ± 2.17	174.6 ± 2.3	175.4 ± 2.43	172.5 ± 2.61	173.7 ± 2.52
Final	176.7 ± 1.21	189.2 ± 3.41 ^b	135.3 ± 1.69 ^a	166.4 ± 3.12	165.6 ± 3.67
Lipid profile					
TC (mg/dl)	86.1 ± 2.30	92.4 ± 1.92	53.21 ± 1.42 ^a	90.6 ± 2.51 ^x	92.7 ± 3.76 ^x
TG (mg/dl)	94.2 ± 3.98	84.6 ± 4.70	52.7 ± 1.54 ^a	92.71 ± 2.26 ^x	95.9 ± 3.91 ^x
HDL-C (mg/dl)	31.6 ± 0.70	33.5 ± 1.95	21.7 ± 0.76 ^b	30.1 ± 1.83 ^y	29.8 ± 1.47 ^z
VLDL-C (mg/dl)	25.2 ± 1.71	23.6 ± 1.84	12.7 ± 0.81 ^a	26.2 ± 1.71 ^x	22.9 ± 3.76 ^y
LDL-C (mg/dl)	31.7 ± 1.76	34.4 ± 1.27	18.6 ± 1.27 ^a	38.1 ± 2.34 ^x	36.7 ± 3.99 ^y
Liver markers					
ALT (IU/L)	37.6 ± 1.71	28.3 ± 1.23 ^a	91.5 ± 2.88 ^a	49.16 ± 1.67 ^x	62.4 ± 3.09 ^y
AST (IU/L)	53.4 ± 2.91	38.8 ± 1.75 ^a	160.2 ± 3.64 ^a	58.7 ± 2.41 ^x	119.2 ± 4.98 ^x
LDH (IU/L)	86.5 ± 3.12	79.24 ± 3.98	184.7 ± 4.18 ^a	96.32 ± 3.57 ^x	124.12 ± 5.17 ^x
TNFα (pg/ml)	117.26 ± 4.96	109.07 ± 3.98	1418.69 ± 11.87 ^a	386.09 ± 5.16 ^x	820.40 ± 7.09 ^x

Table 1. Effects of the test compound, APC on body weight, different serum lipids & liver marker enzymes in the normal and T₄-induced rats. Data are in means ± SEM, n = 7. ^aP < 0.001 and ^bP < 0.01 as compared to their initial b.wt. ^aP < 0.001 and ^bP < 0.01, as compared to the respective control value; whereas ^xP < 0.001, ^yP < 0.01 and ^zP < 0.05 as compared to the respective value of thyroxine (T₄) treated animals.

and 5'D1 were inhibited. In euthyroid animals, APC markedly decreased the concentration of both the thyroid hormones and 5'D1 activity and increased the TSH level.

Changes in hepatic Glucose 6-phosphatase and Sodium Potassium ATPase activities. Following T₄ administration to euthyroid rats, there was a significant increase in the activities of hepatic glucose 6-phosphatase (G-6-Pase) and sodium potassium ATPase (Na⁺-K⁺-ATPase). However, in APC + T₄ and in PTU + T₄ treated rats, activities of both the enzymes were inhibited significantly (Fig. 3b). In APC treated animals also, both the enzymes activities were decreased as compared to their respective control value.

Changes in different serum lipids. As compared to the value of the control group, administration of T₄ decreased the serum concentrations of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C) and high density lipoprotein cholesterol (HDL-C). However, APC or PTU administration in thyrotoxic rats elevated the levels of these serum lipids near to the normal/control values (Table 1). Only in APC treatment in euthyroid animals, no significant differences were found when compared to the control group.

Changes in liver enzymes. A marked increase in the levels of serum alanine transaminase (ALT), aspartate amino transferase (AST) and lactate dehydrogenase (LDH) was observed in L-T₄ treated thyrotoxic rats, whereas,




Figure 3. (a) Changes in concentrations of serum T₃ (ng/ml), T₄ (ng/ml X10), TSH (μU/ml) and hepatic 5'DI (ng/ml T₃ generated/hour/mg protein), following the administration APC (2.0 mg/kg/d) alone or T₄ + APC or T₄ + PTU. Each bar represents the mean ± SEM (n = 7). ^a*P* < 0.001 and ^b*P* < 0.01 as compared to the respective control value; whereas ^x*P* < 0.001 and ^y*P* < 0.01, as compared to the respective value of L-T₄ treated group. (b) Changes in hepatic G-6-Pase (μM of Pi liberated/h/mg protein) and Na⁺-K⁺-ATPase activity (μM of Pi liberated/h/mg of protein) following the administration APC (2.0 mg/kg/d) alone or T₄ + APC or T₄ + PTU in rats. Each vertical bar represents the mean ± SEM. (n = 7). ^a*P* < 0.001 as compared to the respective control value, whereas ^x*P* < 0.001 as compared to the value of L-T₄ treated animals.




Figure 4. (a) Changes in LPO (nM MDA formed/h/mg protein) and lipid hydroperoxides (LOOH, nM/mg protein) in the hepatic tissues of APC (2.0 mg/kg/d) alone or T₄ + APC or T₄ + PTU treated animals. Each vertical bar represents the mean ± SEM. (n = 7). ^a*P* < 0.001 and ^c*P* < 0.05 as compared to the respective control value, whereas ^x*P* < 0.001 as compared to the L-T₄ treated animals. (b) Activities of SOD (units/mg protein), CAT (μM of H₂O₂ decomposed/minute/mg protein), GPx (μ moles of GSH oxidized/mg protein) and GSH (μM GSH/mg protein) in liver tissues following the administration of either T₄ alone or with APC. Each vertical bar represents the mean ± SEM (n = 7). ^a*P* < 0.001, ^b*P* < 0.01 and ^c*P* < 0.05 as compared to the respective control value. ^x*P* < 0.001, ^y*P* < 0.01 and ^z*P* < 0.05 as compared to the respective value of the T₄-induced animals.

their concentrations were decreased significantly in T₄ + APC and in T₄ + PTU treated animals as compared to that of L-T₄-induced rats (Table 1).

Changes in inflammatory cytokine in the serum. Compared to the value of the control animals, serum level of tumor necrosis factor-alpha (TNF-α) was markedly elevated in thyrotoxic rats. But the treatment of T₄-induced animals with APC reduced it significantly. In PTU + T₄ treated group also, level of TNF-α decreased significantly. In APC alone treated group, the value was nearly the same to that of control group (Table 1).

Changes in hepatic lipid peroxidation and in antioxidant levels. In T₄-induced rats, the levels of lipid peroxidation (LPO) products such as thiobarbituric acid reactive substances (TBARS) and lipid hydroperoxides (LOOH) were significantly high as compared to control rats. However, APC administration to thyrotoxic rats or to euthyroid animals significantly reduced the levels of LPO (Fig. 4a). In APC alone treated animals also a significant decrease in LPO and LOOH was observed as compared to that of control animals.

While the activities of antioxidants such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and total glutathione (GSH) content were depleted significantly in the liver of T₄-treated animals,




Figure 5. (a) Results of western blotting on the protein expression of TPO and TSHR in the thyroid gland showing the effects of APC in euthyroid and thyrotoxic animals. (b) Representative western blot of TPO and TSHR quantification showing the down regulation of TPO and high expression of TSHR in the thyroid gland of T_4 -induced thyrotoxic rats. In T_4 + APC and T_4 + PTU treated animals, TPO expression was upregulated and TSHR was down regulated. $^aP < 0.001$ as compared to the control value and $^xP < 0.001$, as compared to the value of the T_4 -induced animals. Data were analyzed by one way analysis of variance (ANOVA) followed by Tukey–Kramer post-hoc test and have been expressed as the mean \pm SEM (n = 5 per each group).

following the administration of APC, the activities of these antioxidants were restored near to control levels. In T_4 + PTU treated groups the values were also more or less similar to that of control (Fig. 4b). Administration of APC alone too increased the antioxidants to a significant level as compared to that of control animals.

Western blot analyses. In the expression of thyroid peroxidase (TPO) and thyroid stimulating hormone receptor (TSHR) marked changes were observed in thyrotoxic rats. TPO expression was significantly down-regulated, while TSHR expression got upregulated. However, treatment of APC or PTU to thyrotoxic rats significantly increased the expression of TPO and decreased the TSHR (Fig. 5a). On quantification of the expressions of TPO and TSHR in thyroid tissues (Fig. 5b), in thyrotoxic animals, a significant decrease in the level of TPO, but an increase in TSHR was observed as compared to their respective control values. However, in APC + T_4 and in PTU + T_4 treated rats, TPO was markedly increased as compared to the value of thyrotoxic animals. Full-length gel has been presented in Supplementary Section (Fig. S2a,b).

Histological changes in the liver and thyroid tissues. The liver of control rat showed a normal histological structure with cords of polyhedral hepatocytes radiating from the central vein, while T_4 -induced liver indicated severe hepatic damage with disorganization of hepatic cords, the central vein and release of cellular inflammatory cells in portal tract. However, administration of APC to L- T_4 -treated rats improved the liver architecture to more or less similar to that of control group by preventing the cellular damage and inflammation. As shown in Fig. 6(a), the hepatocytes count in thyrotoxic group was significantly more as compared to control animals. T_4 -induced rats resulted an increase in necrotic area as compared to that of control animals whereas, APC or PTU treatment reduced the necrotic area significantly as compared to that of T_4 -induced rats (Fig. 6b). In thyrotoxic rats, a significant increase in the number of inflammatory cell counts was observed as compared to that of control. However, the liver sections of T_4 + APC and T_4 + PTU treated rats showed a reduction in inflammatory cell count with respect to hyperthyroid rats (Fig. 6c).

Thyroid gland histology (Fig. 6) from the control and APC alone treated animals exhibited normal histological architecture with multiple follicles consisting of a layer of follicular cells and filled with moderate amount of colloid. However, examination of thyroid gland sections of T_4 -induced rat exhibited decreased thickness of follicular lining of epithelium (Fig. 6d) and decreased follicular cell height (Fig. 6e). Following the treatment with APC or PTU to thyrotoxic animals the follicular sizes and follicular lining of epithelium were nearly normalized.

Discussion

The isolated compound from betel leaf was identified as allylpyrocatechol with a molecular formula, $C_9H_{10}O_2$, deduced on the basis of its spectroscopic analyses (IR, 1H , ^{13}C NMR and GC-MS). Although, this compound was isolated earlier from piper betel plant, investigation on its biological effects were primarily done with respect to antioxidative, gastro-protective and anti-inflammatory properties only^{11,12,14} and practically nothing was studied in relation to the regulation of thyroid dysfunction. Findings of this *in vivo* study clearly indicated the ameliorative nature of the test compound, APC in T_4 -induced hyperthyroid rats, suggesting its therapeutic use in thyrotoxicosis.

The chronic administration of L- T_4 induced thyrotoxicosis in rats as evidenced by marked increase in the level of serum thyroid hormones and in the activity of hepatic 5'D1 (the enzyme, that converts T_4 to T_3), with a decrease in TSH. This was also supported by loss of body weight, which may be due to the increase in the body metabolism by excess amount of circulatory thyroid hormones²². However, when APC was administered to T_4 -induced animals, it decreased the levels of both T_4 and T_3 and increased the serum TSH, suggesting an




Figure 6. Effects of APC on the histological changes in liver and thyroid gland of T_4 treated rats [H and E stain (10x)]. Liver section of control group shows the central vein (CV) surrounded by the radiating cords of hepatocytes, whereas T_4 -induced rat liver shows inflammatory cell infiltrations and cellular damage. In liver section of APC treated animal, cords of normal hepatocytes (H) radiating from the central vein (CV) are seen. In T_4 -induced APC treated rat liver, near normal histological structure is seen with normal hepatocytes. Only moderate degree of liver damage is seen in the T_4 -induced animals that received PTU also. N = necrotic area, IFC = inflammatory cells (arrows). **(a)** In T_4 -induced thyrotoxic liver, an increase in the hepatocytes number was found, but in T_4 + APC and T_4 + PTU groups, there was a reduction in the number of hepatocytes as compared to that of thyrotoxic liver. Data are presented as mean \pm SEM (n = 5 per each group). ^a $P < 0.001$ as compared to the respective control value. ^x $P < 0.001$ as compared to the respective value of the T_4 -induced animals. **(b)** Quantitative analysis of liver necrosis. In T_4 - treated rats the percent necrotic area was increased as compared to that of control rats (n = 5). This was determined by random evaluation of each HE-stained section. However, in T_4 + APC and T_4 + PTU groups, decreased area of necrosis (%) was observed as compared to that of thyrotoxic liver. Data are presented as mean \pm SEM. (n = 5 in each group). ^a $P < 0.001$ as compared to the respective control value. ^x $P < 0.001$ as compared to the respective value of the T_4 - induced animals. **(c)** Histological changes also indicate increased inflammatory cell count in T_4 -induced thyrotoxic liver which is reduced in T_4 + APC and T_4 + PTU treated animals, as compared to the thyrotoxic liver. Data are presented as mean \pm SEM. (n = 5 in each group). ^a $P < 0.001$ as compared to the respective control value. ^x $P < 0.001$ as compared to the respective value of the T_4 - induced animals. Representative photomicrographs of thyroid tissues in H&E-stained images (10x) showing marked changes in thyroid section of APC or T_4 + APC or PTU treated rats. In control rats normal thyroid follicles (F) lined with a single layer of cuboidal follicular cells are seen, while in T_4 -induced rats, thyroid follicles are markedly distended with less amount of colloid. The thyroid sections of animals treated with T_4 + APC or T_4 + PTU show marked improvement in the thyroid follicles. In only APC treated animal, no alteration in the histological structure of thyroid follicles is seen exhibiting nearly normal histological features. F = follicle; C = colloid. **(d)** Changes in the follicular lining epithelium thickness (measured as morphological assessment) of the thyroid gland are seen following APC treatment. While epithelium thickness was reduced in T_4 -induced thyrotoxic rats, thyroid section of T_4 + APC and T_4 + PTU showed almost normal follicular lining epithelium. Data are presented as mean \pm SEM (n = 5 per group).

^a $P < 0.001$ as compared to the respective control value, whereas ^x $P < 0.001$, as compared to the respective value of thyroxin treated animals. (e) It shows a reduction in the follicular cell height in T_4 -induced thyrotoxic rats, but thyroid section of animal, treated with T_4 + APC and T_4 + PTU show normal follicular cell height. Data are presented as mean \pm SEM (n = 5 per group). ^a $P < 0.001$ as compared to the respective control value, whereas ^x $P < 0.001$, as compared to the respective value of thyroxin treated animals.

inhibition in thyroid hormone synthesis and/or their release. Interestingly, hepatic 5'-D1 activity was also inhibited by the test compound, ascertaining that APC has the potential not only to inhibit the glandular synthesis and/or secretion of T_4 , but also the peripheral conversion of T_4 to T_3 , the major pathway of production of latter thyroid hormone. These findings are somewhat similar to the earlier observations with another bioactive compound that exhibited thyroid-inhibitory action in rats¹⁰.

As thyroid hormone synthesis was inhibited by the test drug, attempt was made to reveal its action on the process of iodination of tyrosine molecule, the first step of thyroid hormone synthesis, in which TPO plays an important role²³, i.e., oxidation of inorganic iodide (I^-) to reactive iodine (I^0) for its binding to tyrosine molecule, the main amino acid of the thyroid hormones. In another animal model, less or negligible TPO expression was seen in the absence of TSH/TSHR signalling, indicating that TPO expression is regulated largely by TSH²⁴. Interestingly, in our experimental thyrotoxic rats, not only there was less TSH, but also the expression of TPO was down regulated. However, following the APC treatment in thyrotoxic animals, a significant increase in both the indices was observed. These findings may be compared with an earlier report, in which anti-thyroid compounds such as methimazole and propylthiouracil increased cellular thyroid peroxidase activity in cultured porcine thyroid follicles²⁵. Moreover, as high TSH level is known to increase the level of TPO antibody²⁶, it is quite possible that APC-induced increase in TSH might have directly increased the TPO expression in this investigation.

Thyroid-stimulating hormone and thyrotropin receptor are directly involved in the regulation of thyroid function²⁷. In fact, TSHR plays a pivotal role in thyroid hormone metabolism. Since this receptor responds to TSH and stimulates the production of thyroid hormones, it was suggested earlier that in Graves disease (a condition of hyperthyroidism), the activation of TSHR is seen with low or no TSH^{28,29}. We also observed a higher expression of TSHR protein and lower expression of TPO in L- T_4 -induced thyrotoxic rats that had low TSH level. However, following APC treatment in thyrotoxic animals, there was a marked decrease in TSHR expression and an increase in TPO expression as compared to T_4 -induced rats, confirming that APC suppressed the thyroid function.

Thyroid hormones normally promote metabolic conditions, characterized by weight loss, reduced levels of different serum lipids including cholesterol, TG and HDL^{30,31}. In this study, similar to our earlier finding¹⁰ decreased levels of TC, TG, HDL-C, LDL-C, and VLDL-C were observed in thyrotoxic rats; whereas, treatment with APC restored all these serum lipids near to their normal levels in T_4 -treated rats, further supporting its beneficial effects in thyrotoxicosis.

G-6-pase is often considered as an important enzyme in thyroid function and its activity is closely related to the thyroidal activity or to the circulating levels of thyroid hormones^{32,33}. Interestingly, we also found that the activity of this enzyme was increased by T_4 , but decreased in T_4 -induced APC treated animals, again consolidating its potential to regulate thyrotoxicosis.

An increase in hepatic Na^+/K^+ -ATPase activity was noticed in the thyrotoxic animals, as reported earlier³⁴. However, treatment with APC decreased the same, further supporting the thyro-inhibitory role of APC. This effect of APC was similar to that of PTU in thyrotoxic rats.

An increase in reactive oxygen species induced by L- T_4 always leads to oxidative stress in different tissues including liver, the major target organ of a drug, with consequent lipid peroxidative responses^{35,36}. In this study also, thyrotoxicosis resulted in a marked increase in malondialdehyde (MDA) and lipid hydroperoxides (LOOH) levels with a depletion of antioxidants. Interestingly, following the administration APC in L- T_4 -induced rats, not only tissue LPO was reduced, but also it increased the activities of antioxidants such as SOD, CAT, and GPx, which provide the first line of defence against superoxide and hydrogen peroxides³⁷.

As reported previously, we also found low levels of hepatic GSH content in T_4 -induced animals^{38,39}. Interestingly, following the treatment with APC to thyrotoxic rats, GSH level was normalized. Thus APC could increase the antioxidant levels in liver clearly indicating its efficacy on decreasing oxidative stress provoked by thyrotoxicosis. This may be emphasized that the test compound exhibited better antioxidative effects as compared to that of PTU.

ALT, AST and LDH are considered as sensitive indicators of liver cell injury and their high levels are often associated with hepatic dysfunction⁴⁰. We also observed higher activities of these enzymes in serum of thyrotoxic rats, in response to oxidative stress, induced by Thyrotoxicosis as observed earlier in another study⁴¹. However, following APC treatment, ALT, AST and LDH levels were reduced thus cellular and tissue damage was prevented by APC. This tissue protective effects of APC is in accordance with an earlier report⁴². While studying the cytokine levels an increase in serum TNF- α was found in thyrotoxic animals as compared to the value of control animals. TNF- α has an effective impact on the circulating antibody production during inflammation⁴³. In fact, an increased oxidative stress is known to stimulate the release of different cytokines, including TNF- α and interleukins⁴⁴. This might explain the high levels of TNF- α observed in the thyrotoxic group. Since the levels of TNF- α was significantly lower in rats receiving APC, as compared to the value of thyrotoxic rats, it appears that APC might have a potent anti-inflammatory activity, at least in L- T_4 -induced thyrotoxic rats.

In the liver of thyrotoxic animals, we found an increase in hepatocyte number as reported in an earlier finding⁴⁵. However, treatment with APC restored the normal hepatocytes count. Further, the inflammatory cells count was increased in thyrotoxic liver and less inflammatory cell counts were seen following APC administration which could be the result of consequent inhibition of the production of TNF- α . The hepatic damage, in

terms of necrotic area due to excess thyroid hormones was also observed. This may be related to enhanced lipid peroxidation and higher levels of ALT, AST, LDH and TNF- α in T₄-induced rats. Interestingly, the treatment with APC resulted in a marked decrease in necrotic area when compared to that of thyrotoxic group, suggesting the hepato-protective effects through attenuation of oxidation and inflammatory response in the liver by APC.

With respect to thyroidal histology, while normal thyroid structure with cuboidal to low columnar, small and medium-sized follicles were seen in euthyroid control animals, following L-T₄ administration, marked distortion in its architecture was observed. Similar to the earlier studies^{46,47}, we also found a reduction in the height and epithelial thickness of the follicles and hypertrophied follicles with less amount of colloid in L-T₄ induced rats, which were nearly corrected by APC treatment. APC also decreased T₄ and T₃ levels and increased the TSH concentration, exhibiting anti thyroidal property of the test compound.

In fact, the effects of the APC on thyroidal histology were comparable with that of PTU. An important point that needs to be emphasized here is that the dose of APC that we used *in vivo* is equivalent to a dose of about 130 mg/kg/day in human, according to dose translation from animal to human⁴⁸.

At present, nothing can be said on the exact molecular mechanism(s) of APC effects. One explanation could be that, the inhibition of thyroid functions by the test compound could be the result of decrease in T₄ synthesis and/or secretion at the glandular level and by the reduction of T₄ to T₃ conversion, an important process of T₃ formation. Another key mechanism is that, APC might have ameliorated the thyrotoxicosis by regulating the expression of TPO and TSHR proteins.

In conclusion, the isolated compound allylpyrocatechol exhibited its potential in minimizing the pathophysiology of T₄-induced thyrotoxicosis in rats with additional hepatoprotective effects. Possibly this anti-thyroid action of APC is due to the inhibition of synthesis and/or release of T₄ and by a decrease in the T₃ production, primarily by altering the 5'D1 activity in liver.

On the cellular mechanism of action of the test compound, it seems that APC increased and decreased the expression of thyroidal TPO and TSHR respectively. This may be a novel finding that suggests a beneficial role of our test compound, APC in the amelioration of thyrotoxicosis. Of course, further investigation is required to establish the optimum dose for its therapeutic use.

Limitation. The limitation in this experiment is that we did not study the m-RNA expression and its relationship with protein levels. As the changes in gene expression may not always support the changes in m-RNA expression, we preferred to carry-out only protein expression studies to avoid the uncertainty on the effects of APC in thyroid function.

Materials and Methods

Chemicals and assay kits. Enzyme-linked immunosorbent assay (ELISA) kits for thyroid hormone assays were purchased from Life Technologies Pvt. Ltd., India. For estimations of total cholesterol, triglyceride and high density lipoprotein cholesterol, assay kits were obtained from Span diagnostics Pvt. Ltd., Surat, India. Kits for aminotransferase enzymes, alanine transaminase, aspartate transaminase, and lactate dehydrogenase were from Erba diagnostic pvt. Ltd., GmbH, Germany. ELISA kit for TNF- α was purchased from Ray Biotech Inc, Norcross, GA, USA. While anti-TPO, anti-TSHR, anti- β -actin and nitrocellulose were obtained from Santa Cruz Biotechnology, USA; NC membrane was supplied by Millipore, USA. Jackson Immuno-Research Laboratories Inc. USA supplied HRP-conjugated anti-mouse secondary antibody. Bovine serum albumin (BSA) and Tween-20 were provided by Sigma-Aldrich, USA. All other routine chemicals used in the biochemical studies were purchased from Hi-Media, Mumbai, India.

Plant material. *P. betel* leaves of Mysore variety were purchased from local market, Indore, India. The test plant material was authenticated by a known botanist Prof. A. Serwani and deposited with the voucher number, BL 06102 in School of Life Sciences, Devi Ahilya University, Indore, India.

Extraction and isolation. Ethanol extract of the *P. betel* was prepared from its dry leaf powder and then APC was isolated from it using the procedure reported earlier²¹. Dried powder of *P. betel* leaf (250 g) was extracted with 95% ethanol (1 L) for 2 days. The extract was filtered and the supernatant was collected. The process was repeated thrice and all the clear fractions were pooled and evaporated in vacuum. Eight gram of this extract was dissolved in 50 mL of methanol, treated with 0.2 g of activated charcoal and warmed at 60 °C. The insoluble material was removed by filtration and the extract was dried under vacuum and lyophilized to afford the chlorophyll free amorphous yellowish brown solid (yield, 0.98%). This was stored in a vacuum desiccator. The ethanol extract (4.7 g) was chromatographed over a silica gel column and 50 mL of fractions were collected using the gradient elution of 0, 2, 5 and 10% ethyl acetate/hexane followed by 0, 5, 10, 15, 50 and 100% methanol/chloroform (500 mL each). The fraction eluted with 10% ethyl acetate/hexane yielded the compound APC as light yellow oil and the yield was 0.92% (w/w of the extract). The structure of the isolated APC (Fig. 1) was elucidated using different spectral analyses such as IR, NMR and GC/MS.

Spectral data analyses. Gas chromatography mass spectroscopy (GC-MS) analysis of the isolated compound was carried out on JEOL GCMATE II system from Agilent Technologies, USA. The HP-5 column used in GC was of 30 m long and 0.25 mm diameter. Purity of APC was determined by HPLC using a Shimadzu LC-20AT system equipped with Shimadzu diode array detector. For chromatographic separation, C18 column (4.6 mm \times 250 mm, and particle size 5 μ m), from Agilent Technologies Inc., Santa Clara, CA, USA was employed. The ¹H and ¹³C NMR spectra were recorded on Bruker NMR spectrometer at 500 and 125 MHz respectively in CDCl₃ as solvent and tetramethylsilane (TMS) as the internal standard. Chemical shifts are expressed in δ (ppm).

Animal ethics. Handling of animals, their maintenance and treatment with drugs in animals were conducted according to the guidelines of the Ministry of Social Justice and Empowerment, Government of India (registration No, 779/Po/Ere/S/03/CPCSEA). The experimental procedure was approved by our Institutional Animal Ethical Committee (IAEC) and the Departmental Ethical Committee (School of Life Science, DAVV, Indore, India).

Experimental design. In our first experiment, an initial screening of three different concentrations (0.5, 1.0, and 2.0 mg/kg, suspended in 1% acacia gum) of the test compound was made to find out the most effective dose of APC in L-T₄ treated (pre standardized 500 µg/kg of L-T₄ for 12 days) female thyrotoxic rats. We observed that both T₃ and T₄ levels were significantly inhibited at 2.0 mg/kg without any hepatotoxic effects (data shown in Supplementary Section, Table 1). Based on these results, the effective dose, 2.0 mg/kg was selected for the next experiment.

In the second experiment, healthy female Wister rats, weighing 170 ± 10 g were divided in to five groups and in each group seven animals were kept. The control animals (group 1) received gum acacia in distilled water (per oral, p.o); Group 2, 4 and 5 were first injected with 500 µg/kg of L-T₄ for 12 days to induce thyrotoxicosis. While T₄-induced group 4 animals were treated with APC (2.0 mg/kg, p.o.), animals of group 5 received PTU (10 mg/kg, i.p.) and animals of group 3 received only APC by oral route for 30 days. The doses here we used for PTU and T₄ were taken from our previous published work³¹. To avoid the circadian interference, all the treatments were scheduled between 10.00 and 11.00 h of the day and the total duration of the experiment was 6 weeks. After 6 weeks, the overnight fasted rats were anesthetized and sacrificed by cervical decapitation. Blood was collected, allowed to clot and serum was separated by centrifugation. Immediately the liver and thyroid glands were removed and washed with cold saline. Liver tissue homogenate (10%, w/v) was prepared in ice-cold phosphate buffered saline (0.1 M, pH 7.4) and centrifuged for 20 min at 10,000 × g and at 4 °C. The supernatant was used for the assay of different biochemical parameters.

Assay of serum thyroid hormones, TSH and TNF-α. T₃, T₄ and TSH were estimated in serum by ELISA using the commercial kit from Life Technologies (India) Pvt. Ltd. following the manufacturer's instructions. The levels of TNF-α in serum was estimated using the commercially available specific ELISA kit.

Hepatic 5'DI activity. The activity of 5'DI was measured in liver homogenates with the protocol used earlier by Kodding *et al.*⁴⁹ with little alteration. Liver of each animal was homogenized in ice-cold phosphate buffer (0.15 M, pH 7.2) with 0.25 M sucrose and 5 mM EDTA. The homogenates were centrifuged at 2000 g for 30 min at 4 °C and the supernatants were collected. To 100 µl of supernatants, 10 µl of T₄ (4 µM) and 10 µl of dithiothreitol (DTT) (4 mM) were added and kept for incubation at 37 °C for one hour. The reaction was stopped by the addition of 800 µl of absolute ethanol. The amount of T₃ formed was measured using the T₃ ELISA kit.

ALT, AST and LDH activities. Enzyme activities of ALT, AST and LDH were estimated in serum according to the manufacturer's instructions mentioned in the specific kit.

Concentration of serum lipids. For the estimation of serum TC, TG and HDL-C, commercial kits were used. LDL-C and VLDL-C values were calculated out, for which the formula of Friedwald *et al.*⁵⁰ was used. The formula is, LDL-C = Total cholesterol – (HDL-C + VLDL-C) and VLDL-C = Triglycerides/5.

Assay of Glucose-6-phosphatase. The activity of this enzyme was assayed by the method Bagniski *et al.*⁵¹. For this we measured the amount of inorganic phosphate (Pi) released from an incubation reaction (for 15 min and at 30 °C) mixture consisting of liver supernatant (0.3 mL), 0.7 mL of citrate buffer (0.1 M, pH 6.5) and 0.3 mL of glucose-6-phosphatase (20 mM). The reaction was stopped by the addition of 1 mL of 10% TCA, and then centrifuged to obtain the clear supernatant which was processed for the estimation of Pi by the method of Fiske and Subbarow⁵². Absorbance was taken at 680 nm.

Assay of Na⁺-K⁺-ATPase. The hepatic Na⁺-K⁺-ATPase activity was determined by the method of Esmann *et al.*⁵³ in which the liberated inorganic phosphate was measured by the method of Fiske and Subbarow⁵². The enzyme activity was expressed in nmol of Pi liberated/hr/mg protein. The routine method of Lowry *et al.*⁵⁴ was used for the estimation of tissue protein.

Study of oxidative stress markers: LPO and LOOH. In liver tissue LPO was studied by measuring the amount of thiobarbituric acid reactive substances (TBARS) using the method of Ohkawa *et al.*⁵⁵. To the liver homogenate (0.2 mL), the reaction mixture consisting of 0.2 mL of 8.1% sodium dodecyl sulfate (SDS), 1.5 mL of 20% acetic acid (pH 3.5) and 1.5 mL of 0.8% of thiobarbituric acid (TBA) were added, followed by heating for 1 hr at 95 °C and cooled. To this, 5 mL of n-butanol and pyridine mixture (15:1 v/v) were added, centrifuged at 5000 rpm for 20 min and the absorbance of organic layer was measured at 532 nm. The unit for expression of LPO was nM MDA formed/h/mg protein.

For measuring lipid hydroperoxides levels, the method of Jiang *et al.*⁵⁶ was followed. In brief, to 0.1 mL of liver supernatant, 0.9 mL of Fox reagent was added and incubated for 30 min in room temperature, centrifuged and the absorbance of upper layer was taken at 560 nm. It was finally expressed in nM of LOOH formed/mg protein.

Assessment of antioxidants. *Superoxide dismutase (SOD).* The SOD activity in hepatic tissue was estimated using the method of Marklund and Marklund⁵⁷. In brief, to 20 µl of liver homogenate, 2 mL of 50 mM

Tris-HCl buffer (pH 8.2) and 1 mL (2 mM) pyragallol were added and absorbance was measured at 420 nm for 3 min. Inhibition of the rate of pyragallol autooxidation by 50% is considered as one unit of the enzyme activity.

Catalase activity. Catalase (CAT) activity in liver was estimated according to the method of Aebi⁵⁸. Liver homogenate (50 µl) was added to 1.0 mL of 50 mM phosphate buffer (pH 7). Then the reaction was initiated by the addition of 1 mL of 30 mM H₂O₂. The decrease in absorbance due to H₂O₂ decomposition was read at 240 nm for 3 min at the interval of 60 sec and the enzyme activity was expressed in µM of H₂O₂ decomposed/min/mg protein.

Estimation of reduced glutathione (GSH). The amount of GSH level was measured by the method of Ellman⁵⁹. Liver supernatant (0.5 mL) was first precipitated with 2.0 mL of 5% TCA., centrifuged and the clear supernatant (1.0 mL) was added with 0.5 mL of Ellman's reagent and 3.0 mL of phosphate buffer. GSH reaction with DTNB produced a yellow-colored complex (2-nitro-5-mercaptobenzoic acid) whose absorbance was read at 412 nm.

Glutathione peroxidase (GPx) assay. The assay procedure of Rotruck *et al.*⁶⁰ was followed for the estimation of GPx. To the reaction mixture (0.2 mL of 0.4 M tris buffer at pH 7.0, 0.2 mL of ethylene diamine tetracetic acid, 0.1 mL of sodium azide), 0.5 mL of liver homogenate was added. To this mixture, further 0.2 mL of glutathione and 0.1 mL of H₂O₂ were added and incubated at 37 °C for 10 min. To stop the reaction. 0.5 mL of 10% TCA was added, centrifuged and the supernatant was processed for the estimation of glutathione. GPx activity was expressed in µg of GSH consumed/min/mg protein.

Western blotting. As carried out earlier⁶¹, individual protein samples (20 µg each) extracted from thyroid gland were separated on a 12% SDS-polyacrylamide gel and then transferred on to a nitrocellulose membrane electrophoretically. The membrane was blocked in a 5% BSA and 0.5% Tween-20 for 1 h with mild shaking at room temperature followed by an overnight incubation at 4 °C with the primary antibodies, anti-TPO (1:2000 dilutions), anti-TSHR (1:2000 dilutions) and internal loading control β-actin (1:2000 dilutions) overnight at 4 °C. After washing thrice with sterile phosphate buffer saline (PBS) and 0.05% Tween-20, incubated with horseradish peroxidase (HRP) -conjugated secondary anti-mouse antibody (1:5000 dilutions) for 1 h at room temperature. The membrane was then developed using enhanced chemiluminescence (ECL), Thermo Scientific, Pierce, USA, and visualized using ChemiDoc™ MP Imaging system (Bio-Rad, USA). Western blot images were quantified using image Lab™ software version 5.1 (Bio-Rad).

Histological analyses of thyroid and liver tissues. Liver and thyroid tissues were fixed in 10% neutral formalin and embedded in paraffin. The sections were cut into (5-µm thickness), stained with hematoxylin-eosin (H & E) and were observed under light microscopy (10x magnification). Quantification of morphometric changes of thyroid follicular cell height, thyroid epithelium thickness and hepatocytes count has been performed by ImageJ NIH analysis software, as done earlier by Hwang *et al.*⁶².

Statistical analysis. All values were expressed as mean ± SEM. Results were statistically analysed using the Graph-Pad Instat software, by one-way analysis of variance (ANOVA) followed by post-hoc Tukey–Kramer multiple comparison test. A level of *P* < 0.05 was considered statistically significant. Only T₄-induced rats and APC alone treated rats were compared with normal rats and APC, PTU treated rats were compared with T₄-treated animals.

References

- Singh, I. & Hershman, J. M. Pathogenesis of Hyperthyroidism. *Compar Physiol.* **6**, 67–79 (2016).
- Videla, L. A. Energy metabolism, thyroid calorogenesis, and oxidative stress: Functional and cytotoxic consequences. *Redox Rep.* **5**, 265–275 (2000).
- Anne, H., Vander, Spek, A. H., Fliers, E. & Boelen, A. The classic pathways of thyroid hormone metabolism. *Mol Cell Endocrinol.* **458**, 29–38 (2017).
- Orozco, A., Valverde, R. C., Olvera, A. & García, G. C. Iodothyronine deiodinases: A functional and evolutionary perspective. *J. Endocrinol.* **215**, 207–219 (2012).
- Braverman, L. & Utiger, R. Introduction to thyrotoxicosis. In Braverman, L. & Utiger, R. eds *The Thyroid*. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 453–455 (2005).
- Mittra, E. S., Niederkohr, R. D., Rodriguez, C., El-Maghraby, T. & McDougall, I. R. Uncommon causes of thyrotoxicosis. *J. Nucl. Med.* **49**, 265–278 (2008).
- Berstein, L. M. The effect of physiological doses of thyroxin on the level of cyclic adenosine 3',5'- monophosphate in pituitary and anterior hypothalamus of male rats of different age. *Endocrinologie* **75**, 29–34 (1980).
- Satav, J. G. & Katyare, S. S. Effect of experimental thyrotoxicosis on oxidative phosphorylation in rat liver, kidney and brain mitochondria. *Mol Cell Endocrinol.* **28**, 173–189 (1982).
- Pasyechko, N. V. *et al.* Ultra structural liver changes in the experimental thyrotoxicosis. *Pol J Pathol.* **68**, 144–147 (2017).
- Panda, S. & Kar, A. Protective effects of 5,7,4'-trihydroxy-6,3'-dimethoxy-flavone 5-O-α-l-rhamnopyranoside, isolated from *Annona squamosa* leaves in thyrotoxicosis and in hepatic lipid peroxidation in rats. *Bioorg Med Chem Lett.* **25**, 5726–5728 (2015).
- Zdrojewicz, Z., Kosowski, W., Królikowska, N., Stebnicki, M. & Stebnicki, M. R. Betel - the fourth most popular substance in the world. *Pol Merkuri Lekarski.* **39**, 181–185 (2015).
- Fazal, F. *et al.* The phytochemistry, traditional uses and pharmacology of Piper Betel Linn. (Betel Leaf): A pan-asiatic medicinal plant. *Chin J Integr Med.* <https://doi.org/10.1007/s11655-013-1334-1> (2014 Aug 26).
- De, S., Kundu, S., Chatterjee, U., Chattopadhyay, S. & Chatterjee, M. Allylpyrocatechol attenuates methotrexate-induced hepatotoxicity in a collagen-induced model of arthritis. *Free Radic Res* **52**, 698–711 (2018).
- Haslan, H., Suhaimi, F. H., Thent, Z. C. & Das, S. The underlying mechanism of action for various medicinal properties of Piper betel (betel). *Clin Ter.* **166**, 208–214 (2015).

15. Yadav, S. K., Adhikary, B., Bandyopadhyay, S. K. & Chattopadhyay, S. Inhibition of TNF- α , and NF- κ B and JNK pathways accounts for the prophylactic action of the natural phenolic, allylpyrocatechol against indomethacin gastropathy. *Biochim Biophys Acta*. **1830**, 3776–3786 (2013).
16. Sarkar, D. *et al.* The antioxidant activity of allylpyrocatechol is mediated via decreased generation of free radicals along with escalation of antioxidant mechanisms. *Phytother Res*. **27**, 324–329 (2013).
17. Yadav, S. K., Adhikary, B., Maity, B., Bandyopadhyay, S. K. & Chattopadhyay, S. The gastric ulcer-healing action of allylpyrocatechol is mediated by modulation of arginase metabolism and shift of cytokine balance. *Eur J Pharmacol*. **614**, 106–113 (2009).
18. Panda, S. & Kar, A. Dual role of betel leaf extract on thyroid function in male mice. *Pharmacol Res*. **38**, 493–496 (1998).
19. Cooper, D. S. Antithyroid drugs. *N Engl J Med*. **3**(352), 905–917 (2005).
20. Koenig, R. J. Regulation of type 1 iodothyronine deiodinase in health and disease. *Thyroid*. **15**, 835–840 (2005).
21. Rathee, J. S. *et al.* Antioxidant activity of piper betel leaf extract and its constituents. *J Agric Food Chem* **54**, 9046–9054 (2006).
22. Pakdel, R. *et al.* A comparison between the effects of Portulaca oleracea seeds extract and valsartan on echocardiographic and hemodynamic parameters in rats with levothyroxin-induced thyrotoxicosis. *Avicenna J Phytome* **8**, 276–285 (2018).
23. Taurog, A. Hormone synthesis: thyroid iodine metabolism. In *The Thyroid: A Fundamental and Clinical Text*, 8th ed. Eds Braverman, L. E., editor & Utiger, R. D. editor. Philadelphia: Lippincott Williams & Wilkins, pp. 61–85 (2000).
24. Postiglione, M. P. *et al.* Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland. *Proc Natl Acad Sci USA* **99**, 15462–15467 (2002).
25. Sugawara, M., Sugawara, Y. & Wen, K. Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles. *Thyroid* **9**, 513–518 (1999).
26. Roy, G. & Mughesh, G. Selenium analogues of antithyroid drugs—recent developments. *Chem Biodivers* **5**, 414–439 (2008).
27. Farid, N. R. & Szkudlinski, M. W. Minireview: structural and functional evolution of the thyrotropin receptor. *Endocrinology* **145**, 4048–4057 (2004).
28. Akamizu, T. *et al.* Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies. *Proc Natl Acad Sci USA* **87**, 5677–5681 (1990).
29. Morshed, S. A. & Davies, T. F. Graves' Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies. *Hormone and Metab Res* **47**, 727–734 (2015).
30. Kumar, N., Kar, A. & Panda, S. Pyrroloquinoline quinone ameliorates l-thyroxin-induced hyperthyroidism and associated problems in rats. *Cell Biochem Funct* **32**, 538–546 (2014).
31. Hwang, J. H. *et al.* MOK, a pharmacopuncture medicine, regulates thyroid dysfunction in L-thyroxin-induced hyperthyroidism in rats through the regulation of oxidation and the TRPV1 ion channel. *BMC Complement Altern Med* **17**, 535–538 (2017).
32. Nehal, M. & Baquer, N. Z. Changes in hexokinase and glucose-6-phosphate dehydrogenase in red cells during hypo and hyperthyroidism. *Biochem Int*. **19**, 193–199 (1989).
33. Brent, G. A. Clinical practice. *Graves' disease*. *N Engl J Med*. **358**, 2594–2605 (2008).
34. Lin, M. H. & Akera, T. Increased (Na⁺ - K⁺ - ATPase) concentration in various tissues of rats caused by thyroid hormone treatment. *J. Biol. Chem*. **253**, 723–726 (1978).
35. Videla, L. A. Energy metabolism, thyroid calorigenesis, and oxidative stress, Functional and cytotoxic consequences. *Redox Rep* **5**, 265–275 (2000).
36. Venditti, P. & Di Meo, S. Thyroid hormone-induced oxidative stress. *Cell Mol Life Sci* **63**, 414–434 (2006).
37. Halliwell, B. & Gutteridge, J. M. C. *Free Radicals in Biology and Medicine*. 3rd ed. New York: Oxford University Press (1999).
38. Fernández, V. & Videla, L. A. Hepatic glutathione biosynthetic capacity in hyperthyroid rats. *Toxicol Lett* **16** **89**(2), 85–89 (1996).
39. Maddaiah, V. T. Glutathione correlates with lipid peroxidation in liver mitochondria of triiodothyronine-injected hypophysectomized rats. *FASEB J*. **4**, 1513–1518 (1990).
40. Liju, V. B., Jeena, K. & Kuttan, R. Acute and subchronic toxicity as well as mutagenic evaluation of essential oil from turmeric (*curcuma longa* l). *Food Chem. Toxicol*. **53**, 52–61 (2013).
41. Messarah, M. A. *et al.* Influence of thyroid dysfunction on liver lipidperoxidation and antioxidant status in experimental rats. *Exp. Toxicol. Pathol* **62**, 301–310 (2010).
42. Gomaa, A. M. & Abd El-Aziz, EA. Omega-3 fatty acids decreases oxidative stress, tumor necrosis factor-alpha, and interleukin-1 beta in hyperthyroidism-induced hepatic dysfunction rat model. *Pathophysiology*. **23**, 295–301 (2016).
43. Davis, G. S., Pfeiffer, L. M. & Hemenway, D. R. Persistent overexpression of interleukin-1 beta and tumor necrosis factor-alpha in murine silicosis. *J Environ Pathol Toxicol Oncol* **17**, 99–114 (1998).
44. Perra, A. *et al.* Columbano Thyroid hormone (t3) and tr betaagonist gc-1 inhibit/reverse nonalcoholic fatty liver in rats. *FASEB J*. **22**, 2981–2989 (2008).
45. Subudhi, U., Das, K., Paital, B., Bhanja, S. & Chainy, G. B. Alleviation of enhanced oxidative stress and oxygen consumption of L-thyroxin induced hyperthyroid rat liver mitochondria by vitamin E and curcumin. *Chem Biol Interac*. **173**, 105–114 (2008).
46. Njia, M., Ali, R. M. U., Mirela, U. & Cakic-Milosevic, M. Histological and ultrastructural alterations of rat thyroid gland after short-term treatment with high doses of thyroid hormones Saudi. *Journal of Biological Sciences* **24**, 1117–1125 (2017).
47. Kim, S. M. *et al.* Antioxidant and protective effects of Bupleurum falcatum on the L-thyroxin-induced hyperthyroidism in rat. *Evidence-Based Complementary and Alternative Medicine*. 578497, <https://doi.org/10.1155/2012/578497> (2012).
48. Mordenti, J. & Chappell, W. The use of interspecies scaling in toxicokinetics. In Yacobi, A., Kelly, J & Batra, V. (eds) *Toxicokinetics and new drug development*. Pergamon, New York, pp 42–96 (1989).
49. Ködding, R., Fuhrmann, H. & von zur Mühlen, A. Investigations on iodothyronine deiodinase activity in the maturing rat brain. *Endocrinol* **118**, 1347–1352 (1986).
50. Friedwald, W. T., Levi, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. *Clin Chem*. **18**, 499–502 (1972).
51. Baginsky, E. S., Fod, P. P. & Zak, B. In Bregmeyer, H. (Ed.), *Methods in Enzymatic Analysis*. Academic Press, New York, pp. 876–880 (1974).
52. Fiske, C. H. & SubbaRow, Y. The colorimetric determination of Phosphorous. *J. Biol. Chem* **66**, 375–400 (1925).
53. Esmann, M. ATPase and phosphate activity of Na⁺-K⁺-ATPase: Molar and specific activity, protein determination. *Methods Enzymol*. **156**, 105–115 (1988).
54. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with Folin-phenol reagent. *J Biol Chem*. **193**, 265–275 (1951).
55. Ohkawa, H., Ohishi, N. & Yagi, K. Assays of lipid peroxides in animal tissues by thiobarbituric acid reaction. *Annal Biochem* **95**, 351–358 (1979).
56. Jiang, Z. Y., Hunt, J. V. & Wolff, S. P. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. *Anal. Biochem* **202**, 384–389 (1992).
57. Marklund, S. & Marklund, G. Involvement of superoxide anion radical in the oxidation of pyrogallol: a convenient assay for superoxide dismutase. *Eur J Biochem*. **47**, 469–474 (1974).
58. Aebi, H. Catalase. In Bergmeyer, H. U. (Ed.), *Methods of Enzymol*. Academic Press, New York, **2**, 276–286 (1983).
59. Ellman, G. L. Tissue sulfhydryl groups. *Arch. Biochem. Biophys* **33**, 574–576 (1959).
60. Rotruck, J. T. *et al.* Selenium: biochemical role as a component of glutathione peroxidase. *Science* **179**, 588–590 (1973).

61. Panda, S., Sharma, R. & Kar, A. Chavibetol corrects thyrotoxicosis through alterations in thyroid peroxidase. *Naunyn Schmiedebergs Arch Pharmacol.* **392**, 541–550 (2019).
62. Hwang, J. H. *et al.* Therapeutic effects of acupuncture with MOK, a polyherbal medicine, on PTU-induced hypothyroidism in rats. *Exp Ther Med.* **16**, 310–320 (2018).

Acknowledgements

Department of Science and Technology (DST), New Delhi, India funded this work under Women Scientist scheme to Dr. S. Panda [REF: SR/WOS-A/LS-407]. We thank Mr. Arif Khan for assisting us in computation of the graphs.

Author Contributions

A.K. and S.P. prepared the protocol of the experiments. S.P. conducted the whole experiment and wrote the entire manuscript. Editing of the manuscript was done by A.K. and R.S. who also provided suggestions on the analysis and interpretation of the data. S.B. and M.S. performed the western blot analyses and analysed the data. M.S. also helped in histological study. All the authors went through the data, before the manuscript was prepared.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-48653-9>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019